Fundraising Fox

Metabolon

Durham, US · Delaware corporation · 5 known investors

Metabolon provides metabolomics services and bioinformatics tools that measure small molecules to give biological context to research data. It serves biopharma, public health, consumer wellness, agriculture, and academic research clients across discovery, clinical, and translational studies.

AI & Machine LearningBiotechHealthtech

Founders & leadership

JA
John A. RyalsFounder
GM
Gerald M. Haines IIExecutive
RFRohan F. Hastie
Rohan F. HastieExecutive

Board

JO
John OxaalBoard director
RS
R. Scott BarryBoard director
RJ
R. John FletcherBoard director
BJ
B. Jefferson ClarkBoard director
CKChristopher Kersey
Christopher KerseyBoard directorFounding Managing Partner at Havencrest Capital Management
GF
Guy FishBoard director
CA
Carol A. MarinoBoard director
JL
Jan LundbergBoard director
RC
Robert CascellaBoard director

Investors · 5

Camden PartnersOwings Mills
Essex Woodlands Healthcare PartnersNew York · $20M – $80M
Havencrest Capital ManagementDallas
Revelation PartnersSausalito · $5M – $50M
Syngenta Group VenturesreportedDurham · $500K – $5Mvia David Pierson · board

Reported raises · per SEC filings

Form D private placements

$89.4M disclosed across 7 rounds · 2015–2024

▶$7.5MraisedJan 2025 · 11 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Gerald M. Haines IIExecutive Officer
  • John OxaalDirector
  • Jan LundbergDirector
  • R. Scott BarryDirector
  • Robert CascellaDirector
  • R. John FletcherDirector
  • Rohan F. HastieExecutive Officer, Director
  • Todd SchermerhornDirector
Offering amount
$16.4M
Amount sold
$7.5M
First sale
Dec 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedNov 2022 · 11 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jan LundbergDirector
  • Todd SchermerhornDirector
  • Rohan F. HastieExecutive Officer, Director
  • R. John FletcherDirector
  • R. Scott BarryDirector
  • Robert CascellaDirector
  • John OxaalDirector
  • John KurtzweilExecutive Officer
Offering amount
$41.6M
Amount sold
$10M
First sale
Nov 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$21.8MraisedSep 2020 · 11 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • John KurtzweilExecutive Officer
  • R. Scott BarryDirector
  • R. John FletcherDirector
  • Todd SchermerhornDirector
  • David PiersonDirector
  • John OxaalDirector
  • Robert CascellaDirector
  • Rohan F. HastieExecutive Officer, Director
  • Jan LundbergDirector
Offering amount
$48M
Amount sold
$21.8M
First sale
Aug 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.8MraisedMar 2020 · 11 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • R. Scott BarryDirector
  • R. John FletcherDirector
  • John OxaalDirector
  • Rohan HastieExecutive Officer, Director
  • John KurtzweilExecutive Officer
  • Jan LundbergDirector
  • David PiersonDirector
  • Todd SchermerhornDirector
Offering amount
$9M
Amount sold
$7.8M
First sale
Aug 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.3MraisedAug 2018 · 9 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen FurlongExecutive Officer
  • Santo J. CostaDirector
  • John A. RyalsDirector
  • Rohan HastieExecutive Officer, Director
  • B. Jefferson ClarkDirector
  • Rudy HowardDirector
  • John OxaalDirector
  • C. Thomas CaskeyDirector
  • Scott BarryDirector
  • David PiersonDirector
  • John FletcherDirector
Offering amount
$8.3M
Amount sold
$7.3M
First sale
Aug 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30MraisedDec 2016 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • John OxaalDirector
  • John A. RyalsExecutive Officer, Director
  • Scott BarryDirector
  • C. Thomas CaskeyDirector
  • Rudy HowardDirector
  • B. Jefferson ClarkDirector
  • David PiersonDirector
  • Santo J. CostaDirector
  • John FletcherDirector
Offering amount
$30M
Amount sold
$30M
First sale
Aug 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedMar 2015 · 4 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • B. Jefferson ClarkDirector
  • Santo J. CostaDirector
  • John A. RyalsExecutive Officer, Director
  • John OxaalDirector
  • Christopher KerseyDirector
  • C. Thomas CaskeyDirector
  • Rudy HowardDirector
  • Guy FishDirector
  • Carol A. MarinoDirector
Offering amount
$5M
Amount sold
$5M
First sale
Mar 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
BYJU'S418 shared keywordsBYJU'S offers online learning programs, video lessons, and a personalized learning app for students in India, including tutoring and exam-preparation programs for competitive tests such as JEE and NEET.

Companies competing with Metabolon for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$297.7K
National Institutes of Health (NIH)National Institutes of HealthPhase I2006$100K
National Institutes of Health (NIH)National Institutes of HealthPhase I2005$148.1K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Metabolomics Market Demonstrates Long-Term Growth Potential At 17.3% CAGRopenpr.com · Aug 2026Metabolon Launches Peak Science Grant Program to Advance Breakthrough Metabolomics Research - BioSpacebiospace.com · Aug 2026Sell or Invest in Metabolon Stock Pre-IPOnasdaqprivatemarket.com · Mar 2025Metabolon Secures $25 Million of Funding to Accelerate Growthmetabolon.com · Jan 2023Metabolon, Inc. Announces $72 Million in Debt and Equity Financing to Accelerate Advancements in Precision Medicine and Innovative Drug Development Technologies - Metabolonmetabolon.com · Sep 2020Metabolon Raises Additional $15 Million in Funding from Essex Woodlands | Newsewhealthcare.com · Dec 2016Triangle (NC) based Metabolon lands $13.1M round of venture financingwraltechwire.com · Aug 2011

Frequently asked questions

What does Metabolon do?
Metabolon provides metabolomics services and bioinformatics tools that measure small molecules to give biological context to research data. It serves biopharma, public health, consumer wellness, agriculture, and academic research clients across discovery, clinical, and translational studies.
Who founded Metabolon?
Metabolon was founded by John A. Ryals.
Who are Metabolon's investors?
Metabolon's investors include Camden Partners, Essex Woodlands Healthcare Partners, Havencrest Capital Management, Revelation Partners, Syngenta Group Ventures.
How much funding has Metabolon raised?
Metabolon has disclosed $89.4M raised across 7 rounds.
Where is Metabolon headquartered?
Metabolon is headquartered in Durham, US.